Background
One in nine adults in the US has chronic kidney disease, and 82,000 die each year from kidney failure. Diabetes and high blood pressure are the two most common causes, but there are numerous other causes of kidney disease. Untreated, chronic kidney disease leads to kidney failure. Current treatments can slow the progression of chronic kidney disease but there is no treatment that can halt the progression of the disease, or reverse damage that has already occurred. The underlying mechanism in the progression of chronic kidney disease to kidney failure is the accumulation of scar tissue in the kidney due to fibrosis. Fibrosis is pathological scarring that can lead to organ failure and eventual death. Although it is not known what triggers the fibrotic response, kidney fibrosis is characterized by the presence of myofibroblasts, which are cells that produce scar tissue, and also matrix and matrix-remodeling genes. In extreme cases, the fibrosis becomes systemic, encompassing other areas of the body. Nephrogenic systemic fibrosis (NSF) is seen only in patients with kidney failure. Two primary features characterize it: Thickening and hardening of the skin overlying the extremities and trunk, and marked expansion and fibrosis of the dermis in association with CD34-positive myofibrocytes.
UUO Model
Experimental Unilateral Ureter Obstruction (UUO) represents a model for obstructive nephropathy but also allows insight into the process of interstitial fibrosis that is a common characteristic of many chronic nephropathies. Markers of renal fibrosis, such as interstitial fibroblasts, interstitial volume, mRNA and protein expression for collagen I, are all increased in UUO animals, making the UUO model a good experimental system for studying fibrosis. In this model of fibrosis, animals are subject to UUO on Day 0 and the kidneys are removed (for histological assessment of fibrosis) and blood is collected on day 14.
Preclinical Kidney Disease Research Offered by Biomodels – Your Leading Source for Preclinical Research
Kidney disease is a fairly common problem in the United States and many individuals affected by nephritis or kidney disease turn to pharmaceutical companies for help. As the actual disease changes, it is important for pharmaceutical and research companies to continue providing the latest and best in medicine. When continuous preclinical nephritis / kidney disease research is needed, look no further than Biomodels. With over 10 years of independent preclinical research experience, we are often called on by both small and large pharmaceutical companies across the country.
Preclinical Nephritis / Kidney Disease Research
Biomodels understands the importance of medical advancements and the importance of providing safe medicine to individuals affected by certain diseases. It is those reasons why Biomodels goes above and beyond to provide pharmaceutical companies with information far beyond their expectations. The more thorough the preclinical nephritis research, the more thorough of information we can provide to the pharmaceutical companies. This will ensure that the individuals affected by kidney disease are receiving only the best and most effective in medicines.
Trust Biomodels for all of your preclinical research!
If you are ready to find out more about our preclinical nephritis / kidney disease research, contact us today for more information. We can be reached via our online contact form. Once filled out, a Biomodels representative will be in touch to discuss our services. In the meantime, feel free to browse our site for more of our preclinical research services, company info, and much more!
